140 related articles for article (PubMed ID: 9147607)
21. Protein kinase C isozymes as potential targets for anticancer therapy.
Hofmann J
Curr Cancer Drug Targets; 2004 Mar; 4(2):125-46. PubMed ID: 15032665
[TBL] [Abstract][Full Text] [Related]
22. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs.
Chaudhary PM; Roninson IB
J Natl Cancer Inst; 1993 Apr; 85(8):632-9. PubMed ID: 8096875
[TBL] [Abstract][Full Text] [Related]
23. Dexniguldipine hydrochloride, a protein-kinase-C-specific inhibitor, affects the cell cycle, differentiation, P-glycoprotein levels, and nuclear protein phosphorylation in Friend erythroleukemia cells.
Patterson KK; Beckman BS; Klotz DM; Mallia CM; Jeter JR
J Cancer Res Clin Oncol; 1996; 122(8):465-75. PubMed ID: 8698746
[TBL] [Abstract][Full Text] [Related]
24. A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity.
Meyer T; Regenass U; Fabbro D; Alteri E; Rösel J; Müller M; Caravatti G; Matter A
Int J Cancer; 1989 May; 43(5):851-6. PubMed ID: 2714889
[TBL] [Abstract][Full Text] [Related]
25. PKC412--a protein kinase inhibitor with a broad therapeutic potential.
Fabbro D; Ruetz S; Bodis S; Pruschy M; Csermak K; Man A; Campochiaro P; Wood J; O'Reilly T; Meyer T
Anticancer Drug Des; 2000 Feb; 15(1):17-28. PubMed ID: 10888033
[TBL] [Abstract][Full Text] [Related]
26. Cyclin-dependent kinase and protein kinase C inhibitors: a novel class of antineoplastic agents in clinical development.
Kaubisch A; Schwartz GK
Cancer J; 2000; 6(4):192-212. PubMed ID: 11038138
[TBL] [Abstract][Full Text] [Related]
27. The protein kinase C inhibitor CGP41251 suppresses cytokine release and extracellular signal-regulated kinase 2 expression in cancer patients.
Thavasu P; Propper D; McDonald A; Dobbs N; Ganesan T; Talbot D; Braybrook J; Caponigro F; Hutchison C; Twelves C; Man A; Fabbro D; Harris A; Balkwill F
Cancer Res; 1999 Aug; 59(16):3980-4. PubMed ID: 10463595
[TBL] [Abstract][Full Text] [Related]
28. Targeting protein kinase C (PKC) in physiology and cancer of the gastric cell system.
Fährmann M
Curr Med Chem; 2008; 15(12):1175-91. PubMed ID: 18473812
[TBL] [Abstract][Full Text] [Related]
29. Characterisation of novel human lung carcinoma cell lines selected for resistance to anti-neoplastic analogues of staurosporine.
Courage C; Bradder SM; Jones T; Schultze-Mosgau MH; Gescher A
Int J Cancer; 1997 Nov; 73(5):763-8. PubMed ID: 9398059
[TBL] [Abstract][Full Text] [Related]
30. Cellular relocalisation of protein kinase C-theta caused by staurosporine and some of its analogues.
Jones T; Courage C; Hubbard A; Gescher A
Biochem Pharmacol; 1997 May; 53(10):1413-8. PubMed ID: 9260867
[TBL] [Abstract][Full Text] [Related]
31. Potentiation of apoptosis by treatment with the protein kinase C-specific inhibitor safingol in mitomycin C-treated gastric cancer cells.
Schwartz GK; Haimovitz-Friedman A; Dhupar SK; Ehleiter D; Maslak P; Lai L; Loganzo F; Kelsen DP; Fuks Z; Albino AP
J Natl Cancer Inst; 1995 Sep; 87(18):1394-9. PubMed ID: 7658500
[TBL] [Abstract][Full Text] [Related]
32. The staurosporine analog, Ro-31-8220, induces apoptosis independently of its ability to inhibit protein kinase C.
Han Z; Pantazis P; Lange TS; Wyche JH; Hendrickson EA
Cell Death Differ; 2000 Jun; 7(6):521-30. PubMed ID: 10822275
[TBL] [Abstract][Full Text] [Related]
33. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2.
Wang S; Vrana JA; Bartimole TM; Freemerman AJ; Jarvis WD; Kramer LB; Krystal G; Dent P; Grant S
Mol Pharmacol; 1997 Dec; 52(6):1000-9. PubMed ID: 9396780
[TBL] [Abstract][Full Text] [Related]
34. Protein kinase inhibitor, staurosporine, induces a mature neuronal phenotype in SH-SY5Y human neuroblastoma cells through an alpha-, beta-, and zeta-protein kinase C-independent pathway.
Jalava A; Akerman K; Heikkilä J
J Cell Physiol; 1993 May; 155(2):301-12. PubMed ID: 8482723
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.
Begemann M; Kashimawo SA; Choi YA; Kim S; Christiansen KM; Duigou G; Mueller M; Schieren I; Ghosh S; Fabbro D; Lampen NM; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
Clin Cancer Res; 1996 Jun; 2(6):1017-30. PubMed ID: 9816263
[TBL] [Abstract][Full Text] [Related]
36. Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias.
Beck JF; Brügger D; Brischwein K; Liu C; Bader P; Niethammer D; Gekeler V
Jpn J Cancer Res; 2001 Aug; 92(8):896-903. PubMed ID: 11509123
[TBL] [Abstract][Full Text] [Related]
37. Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity.
Conseil G; Perez-Victoria JM; Jault JM; Gamarro F; Goffeau A; Hofmann J; Di Pietro A
Biochemistry; 2001 Feb; 40(8):2564-71. PubMed ID: 11327879
[TBL] [Abstract][Full Text] [Related]
38. PKC-independent modulation of multidrug resistance in cells with mutant (V185) but not wild-type (G185) P-glycoprotein by bryostatin 1.
Spitaler M; Utz I; Hilbe W; Hofmann J; Grunicke HH
Biochem Pharmacol; 1998 Oct; 56(7):861-9. PubMed ID: 9774148
[TBL] [Abstract][Full Text] [Related]
39. Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer.
Carter CA
Curr Drug Targets; 2000 Sep; 1(2):163-83. PubMed ID: 11465069
[TBL] [Abstract][Full Text] [Related]
40. Prospects for targeting protein kinase C isozymes in the therapy of drug-resistant cancer--an evolving story.
O'Brian CA; Ward NE; Stewart JR; Chu F
Cancer Metastasis Rev; 2001; 20(1-2):95-100. PubMed ID: 11831653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
